IPCI.H — Intellipharmaceutics International Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Annual income statement for Intellipharmaceutics International, fiscal year end - November 30th, USD millions except per share, conversion factor applied.
2018 November 30th | 2019 November 30th | 2020 November 30th | 2021 November 30th | 2022 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.71 | 3.48 | 1.4 | 0 | 0.066 |
| Cost of Revenue | |||||
| Gross Profit | 1.59 | 3.45 | 1.4 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 15 | 11.3 | 3.58 | 4.69 | 2.92 |
| Operating Profit | -13.3 | -7.83 | -2.18 | -4.69 | -2.85 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -13.7 | -8.09 | -3.36 | -5.26 | -2.89 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13.7 | -8.08 | -3.39 | -5.15 | -2.89 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.7 | -8.08 | -3.39 | -5.15 | -2.89 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13.7 | -8.08 | -3.39 | -5.15 | -2.89 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.89 | -0.375 | -0.212 | -0.163 | -0.088 |